• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative Safety Analysis of Nabilone Versus Opioids: A Population-Based Cohort Study.纳布啡与阿片类药物的安全性比较:基于人群的队列研究。
J Gen Intern Med. 2024 Nov;39(14):2716-2723. doi: 10.1007/s11606-024-08978-2. Epub 2024 Aug 14.
2
Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.阿片类药物长期用于慢性非癌性疼痛的相关不良事件:Cochrane系统评价概述
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD012509. doi: 10.1002/14651858.CD012509.pub2.
3
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Opioids for cancer pain - an overview of Cochrane reviews.用于癌症疼痛的阿片类药物——Cochrane系统评价综述
Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2.
6
Pain management for women in labour: an overview of systematic reviews.分娩期女性的疼痛管理:系统评价综述
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD009234. doi: 10.1002/14651858.CD009234.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
Antidepressants for chronic non-cancer pain in children and adolescents.用于治疗儿童和青少年慢性非癌性疼痛的抗抑郁药。
Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012535. doi: 10.1002/14651858.CD012535.pub2.
9
Oxycodone for cancer-related pain.羟考酮治疗癌性疼痛。
Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD003870. doi: 10.1002/14651858.CD003870.pub7.
10
Multifactorial and multiple component interventions for preventing falls in older people living in the community.预防社区老年人跌倒的多因素及多成分干预措施。
Cochrane Database Syst Rev. 2018 Jul 23;7(7):CD012221. doi: 10.1002/14651858.CD012221.pub2.

本文引用的文献

1
Association of Average Daily Morphine Milligram Equivalents and Falls in Older Adult Chronic Opioid Users.老年慢性阿片类药物使用者的日均吗啡毫克当量与跌倒的关联。
Pharmacy (Basel). 2024 Apr 3;12(2):62. doi: 10.3390/pharmacy12020062.
2
Analysis of rising cases of adolescent opioid use presentations to the emergency department and their management.分析青少年阿片类药物使用病例在急诊科就诊的上升情况及其管理。
Drug Alcohol Depend. 2024 May 1;258:111136. doi: 10.1016/j.drugalcdep.2024.111136. Epub 2024 Feb 29.
3
Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study.加巴喷丁类药物与慢性阻塞性肺疾病严重加重的风险:基于人群的队列研究。
Ann Intern Med. 2024 Feb;177(2):144-154. doi: 10.7326/M23-0849. Epub 2024 Jan 16.
4
Evaluation of pre-hospital cannabis exposure and hospital opioid utilization in a trauma population: A retrospective cohort.创伤人群院前大麻暴露与医院阿片类药物使用的评估:一项回顾性队列研究。
Injury. 2024 May;55(5):111305. doi: 10.1016/j.injury.2023.111305. Epub 2023 Dec 30.
5
Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials.医用大麻与阿片类药物治疗慢性非癌痛的比较:随机临床试验的系统评价和网络荟萃分析。
BMJ Open. 2024 Jan 3;14(1):e068182. doi: 10.1136/bmjopen-2022-068182.
6
Synthetic cannabinoid for the treatment of severe chronic noncancer pain in children and adolescents.用于治疗儿童和青少年重度慢性非癌性疼痛的合成大麻素。
Can J Pain. 2022 Nov 28;6(1):225-231. doi: 10.1080/24740527.2022.2132138. eCollection 2022.
7
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies.长期和严重的医用大麻和大麻素对慢性疼痛的危害:非随机研究的系统评价。
BMJ Open. 2022 Aug 4;12(8):e054282. doi: 10.1136/bmjopen-2021-054282.
8
Cannabis-Based Products for Chronic Pain : A Systematic Review.基于大麻的产品治疗慢性疼痛:系统评价。
Ann Intern Med. 2022 Aug;175(8):1143-1153. doi: 10.7326/M21-4520. Epub 2022 Jun 7.
9
Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials.医学大麻或大麻素治疗慢性非癌症和癌症相关疼痛:随机临床试验的系统评价和荟萃分析。
BMJ. 2021 Sep 8;374:n1034. doi: 10.1136/bmj.n1034.
10
Morbidity and mortality associated with prescription cannabinoid drug use in COPD.与 COPD 患者处方类大麻素药物使用相关的发病率和死亡率。
Thorax. 2021 Jan;76(1):29-36. doi: 10.1136/thoraxjnl-2020-215346. Epub 2020 Sep 30.

纳布啡与阿片类药物的安全性比较:基于人群的队列研究。

Comparative Safety Analysis of Nabilone Versus Opioids: A Population-Based Cohort Study.

机构信息

Division of Respirology, Department of Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada.

Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.

出版信息

J Gen Intern Med. 2024 Nov;39(14):2716-2723. doi: 10.1007/s11606-024-08978-2. Epub 2024 Aug 14.

DOI:10.1007/s11606-024-08978-2
PMID:39141203
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535096/
Abstract

BACKGROUND

Some have advocated that nabilone be used rather than opioids to manage chronic, noncancer pain, since the former drug may have a better safety profile.

OBJECTIVE

We compared the safety of incident nabilone use relative to incident opioid use with respect to multiple clinically important outcomes.

DESIGN

A population-based, retrospective cohort study.

SETTING

Province of Ontario, Canada.

PARTICIPANTS

Persons aged 12 years and older, diagnosed with a musculoskeletal condition within the past 3 years prior to the index date.

EXPOSURES

Incident nabilone use, with incident opioid use serving as the reference group.

MEASUREMENTS

Within 3 months following the index date, we separately evaluated for pneumonia, motor vehicle accidents, falls or fractures, mental and behavioral disorder due to psychoactive substance use, and all-cause mortality.

RESULTS

A total of 18,863 incident nabilone users were propensity score matched to an equal number of opioid users. In the overall matched analysis, incident nabilone users vs. incident opioid users had significantly lower rates of pneumonia (hazard ratio [HR] 0.78, 95% CI 0.63-0.96), falls or fractures (HR 0.56, 95% CI 0.50-0.64), and all-cause mortality (HR 0.79, 95% CI 0.65-0.95), but significantly higher rate of mental or behavioral disorder (HR 2.23, 95% CI 1.45-3.43). There was no significant difference between groups with respect to rate of motor vehicle accidents.

LIMITATIONS

Unmeasured confounding may have influenced results.

CONCLUSIONS

While usage of nabilone relative to opioids was associated with reduced rates of pneumonia, falls or fractures, and all-cause mortality, it was simultaneously associated with an increased rate of adverse mental health outcomes. This picture of mixed safety results raises concerns with the policy approach of broadly substituting use of opioids with nabilone.

FUNDING SOURCE

Ontario Ministry of Health.

摘要

背景

有人主张,与阿片类药物相比,纳布啡用于治疗慢性非癌性疼痛可能更安全,因为前者可能具有更好的安全性。

目的

我们比较了新诊断使用纳布啡和新诊断使用阿片类药物的安全性,主要针对多种临床重要结局。

设计

基于人群的回顾性队列研究。

地点

加拿大安大略省。

参与者

年龄在 12 岁及以上,在索引日期前的过去 3 年内被诊断为肌肉骨骼疾病。

暴露情况

新诊断使用纳布啡,以新诊断使用阿片类药物作为参照组。

测量指标

在索引日期后的 3 个月内,我们分别评估肺炎、机动车事故、跌倒或骨折、精神和行为障碍与精神活性物质使用以及全因死亡率。

结果

共 18863 例新诊断纳布啡使用者与 18863 例新诊断阿片类药物使用者进行倾向评分匹配。在整体匹配分析中,与新诊断使用阿片类药物相比,新诊断使用纳布啡的患者肺炎发生率显著降低(风险比 [HR]0.78,95%置信区间 [CI]0.63-0.96)、跌倒或骨折发生率显著降低(HR0.56,95%CI0.50-0.64)和全因死亡率显著降低(HR0.79,95%CI0.65-0.95),但精神或行为障碍发生率显著升高(HR2.23,95%CI1.45-3.43)。两组在机动车事故发生率方面没有显著差异。

局限性

未测量的混杂因素可能影响结果。

结论

与使用阿片类药物相比,纳布啡的使用与肺炎、跌倒或骨折和全因死亡率的降低相关,但同时与不良心理健康结局的发生率增加相关。这种混杂的安全性结果引起了对广泛用纳布啡替代阿片类药物政策方法的关注。

资金来源

安大略省卫生部。